The future of treating acute leukemias
Which is the best combination therapy in relapsed and refractory multiple myeloma?
Bone marrow transplant consent: insight into patient motivations
iwAL 2018 day 2 discussion: novel approaches and targeted therapies in AML
Andrew Wei et al.
CTL019 in pediatric and young adult relapsed/refractory acute lymphoblastic leukemia (ALL) patients